SAMSUNG BIOLOGICS CO.,LTD.
Founded 2011, listed 2016 — Samsung Biologics is a biopharma CDMO with 785,000L capacity across five Songdo plants.
As of 2026-10-10, SAMSUNG BIOLOGICS CO.,LTD. has 10 PubMed-indexed papers on record (counted by the MAA Company Index from its own matching of public databases).
Price
Change
Market cap
Business overview
Source: DART corporate disclosureSamsung Biologics was established in 2011 and listed on the KOSPI in 2016 as a biopharmaceutical contract development and manufacturing organization (CDMO); in November 2025 it completed a spin-off creating Samsung Epis Holdings Co., Ltd. and transitioned to a structure focused on its CDMO business. Operating from Songdo, Incheon, the company provides contract manufacturing (CMO) of antibody biologics and contract development (CDO) services including cell line development and process development, supported by its proprietary cell line S-CHOice®, high-concentration formulation platforms S-Tensify™ and S-HiCon™, and antibody candidate selection platform DEVELOPICK™. Its five Songdo plants have combined production capacity of 785,000 liters, and in December 2025 it signed an agreement to acquire 100% of Human Genome Sciences Inc., which operates a 60,000-liter facility in Maryland, USA, while expanding into mRNA, ADC, and cell/gene therapy manufacturing and launching the 'Samsung Organoid' research services brand in June 2025.
Products & technology
- S-CHOice®Proprietary cell line for CDO services
- S-Tensify™High-concentration formulation platform
- DEVELOPICK™Antibody candidate selection platform
- S-HiCon™High-concentration formulation technology
- Samsung OrganoidResearch service for early efficacy evaluation of drug candidates
Key disclosures
KRX KIND via OpenDARTShow 37 more events
Publications
PubMed · affiliation-matched- Comprehensive Engineering of Ionizable Lipid Nanoparticles and mRNA Elements for Next-Generation Vaccines.
ACS nano · 2026-03 · Kim JG, Xu J, Lee D 외 21
- WWP1 gain-of-function drives developmental anoikis through TGFβ pathway during neurodevelopment.
Cell death discovery · 2026-03 · So KH, Lee S, Wong J 외 6
- CD200 Promotes Gastric Cancer Progression and Metastasis by Inducing the β-catenin Signaling Pathway.
Journal of cellular physiology · 2025-10 · Lee H, Bae JM, Shin SP 외 6
- Soluble receptor for advanced glycation end products attenuates sepsis-associated acute kidney injury.
Kidney research and clinical practice · 2025-08 · Kang HY, Park SY, Kim G 외 6
- Stability of Protein Pharmaceuticals: Recent Advances.
Pharmaceutical research · 2024-07 · Manning MC, Holcomb RE, Payne RW 외 8
- Application of Formulation Principles to Stability Issues Encountered During Processing, Manufacturing, and Storage of Drug Substance and Drug Product Protein Therapeutics.
Journal of pharmaceutical sciences · 2023-11 · Vitharana S, Stillahn JM, Katayama DS 외 2
- A multiplexed bacterial two-hybrid for rapid characterization of protein-protein interactions and iterative protein design.
Nature communications · 2023-08 · Boldridge WC, Ljubetič A, Kim H 외 6
- N-terminal selective conjugation method widens the therapeutic window of antibody-drug conjugates by improving tolerability and stability.
mAbs · 2021-01 · Ko MJ, Song D, Kim J 외 8
- WHO implementation workshop on guidelines on procedures and data requirements for changes to approved biotherapeutic products, Seoul, Republic of Korea, 25-26 June 2019.
Biologicals : journal of the International Association of Biological Standardization · 2020-05 · Wadhwa M, Kang HN, Jivapaisarnpong T 외 55
- p62/SQSTM1/Sequestosome-1 is an N-recognin of the N-end rule pathway which modulates autophagosome biogenesis.
Nature communications · 2017-07 · Cha-Molstad H, Yu JE, Feng Z 외 23
Patents
KIPRIS · applicant-matchedPCT · Published · 2025-10 · Application PCT/KR2025/015646
PCT · Published · 2025-08 · Application PCT/KR2025/012398
PCT · Published · 2025-08 · Application PCT/KR2025/012064
US · Published · 2025-07 · Application 19266684
Published · 2025-05 · Application 1020250071092
Published · 2025-05 · Application 1020250071373
Published · 2025-03 · Application 1020250034661
PCT · Published · 2024-12 · Application PCT/KR2024/020402
Published · 2024-12 · Application 1020240187212
PCT · Published · 2024-11 · Application PCT/IB2024/000666
Show 32 more patents
Published · 2024-11 · Application 1020240154459
Published · 2024-10 · Application 1020240150744
EP · Published · 2024-05 · Application 24815798.4
PCT · Published · 2024-05 · Application PCT/KR2024/007048
Published · 2024-05 · Application 1020240067763
EP · Published · 2024-05 · Application 24811428.2
PCT · Published · 2024-05 · Application PCT/KR2024/007030
Published · 2024-05 · Application 1020257040389
Published · 2024-03 · Application 1020240030459
US · Published · 2023-12 · Application 19144030
EP · Published · 2023-12 · Application 23912908.3
PCT · Published · 2023-12 · Application PCT/KR2023/021643
Registered · 2023-03 · Application 1020230029611
Registered · 2023-03 · Application 1020230029612
Rejected · 2023-02 · Application 1020230022350
US · Published · 2023-02 · Application 18849790
EP · Published · 2023-02 · Application 23775156.5
PCT · Published · 2023-02 · Application PCT/KR2023/002034
Registered · 2022-12 · Application 1020220185424
Registered · 2022-11 · Application 1020220155189
Registered · 2022-11 · Application 1020220144163
Registered · 2022-11 · Application 1020220144524
Registered · 2022-10 · Application 1020220140117
Registered · 2022-03 · Application 1020220036318
US · Published · 2022-01 · Application 18037728
EP · Published · 2022-01 · Application 22724398.7
PCT · Published · 2022-01 · Application PCT/IB2022/050499
US · Published · 2021-12 · Application 18259375
EP · Published · 2021-12 · Application 21915801.1
PCT · Published · 2021-12 · Application PCT/KR2021/020103
Published · 2021-12 · Application 1020210190482
Registered · 2020-11 · Application 1020200157667
AI reads
MAA server logs · IP-verifiedPulled records become part of each AI's index and keep feeding its answers. When an AI cites from that index, nothing reaches our server — so actual citations are uncounted here and exceed this number.
Times an AI needed something not yet in its index and fetched this page fresh while answering. Citations served from the index leave no trace here.
Collected as raw material for future answers.
Queries from users who connected this index to their own AI.
- OpenAIChatGPT-Userlive6
- OpenAIOAI-SearchBot155
- GoogleGoogleOther38
- PerplexityPerplexityBot9
- AnthropicClaudeBot2
- MicrosoftBingbot1
Measured since Aug 27, 2026 · 5 AI engines · last read Oct 8, 2026
User-agent strings can be forged, so we do not count them at face value. We count only requests matched against vendor-published IP ranges, or confirmed by forward-verified reverse DNS. MCP queries are actual calls to this index's tool endpoint.
Connect this company index directly to your AI
Connect it to ChatGPT or Claude, and your AI queries the full record — profiles, financials, stock data, regulatory approvals, clinical trials, publications and patents — for SAMSUNG BIOLOGICS CO.,LTD. and every listed Korean medical, bio and AI company.
How to connect (MCP)Companies in the same categoryPharma & CDMO
Founded in 1941 and listed on the KOSPI in 1975, Ildong Holdings is the holding company of the Ildong Pharmaceutical Group, overseeing pharmaceutical, aesthetic medical device, and drug development affiliates.
Founded in 1941 and listed on the KOSPI in 1975, Yuyu Pharma is a pharmaceutical company with a co-promotion agreement with Dong-A ST for Tanamin.
Founded and listed on the KOSPI in 2016, Il Dong Pharmaceutical manufactures products including the Aronamin vitamin line.
Founded 2000, KOSDAQ-listed 2009, Medy-Tox develops and exports botulinum toxin biopharmaceuticals including Meditoxin and Innotox.
KOSPI-listed comprehensive pharmaceutical company specializing in blood products and vaccines, with FDA-approved immunoglobulin ALYGLO.
KOSPI-listed pharmaceutical company behind Coldwon cold medicine and Jangdaewon probiotics, developing a P-CAB drug pipeline.
Founded in 2006 and listed on KOSDAQ in 2020, Genolution is a molecular diagnostics and RNAi company producing nucleic acid extraction reagents and devices.
Ahn-Gook Pharmaceutical sells the cough/expectorant drug Sinecuran and the eye-health supplement Tobicom.
Founded in 2003 and listed on KOSDAQ in 2015, Corestem Chemon develops stem cell therapies and provides nonclinical CRO services, including the ALS treatment Neuronata-R.
Founded 2005, KOSDAQ-listed 2022, BIO-FD&C develops plant-cell platform-based cosmeceutical materials and biopharma pipelines.
KOSPI-listed comprehensive pharma company behind Amaryl diabetes drug and the USD 86.25M HL5101 anticancer out-license deal.
Founded in 2007, SK Innovation is an energy company spanning oil, chemicals, batteries, and LNG, merged with SK E&S in 2024.
Sources and updates
Counts on this page are not company-reported figures. MAA matched records from DART, the Korean MFDS, the US FDA, ClinicalTrials.gov, PubMed and KIPRIS to this company itself, by business registration number or registered name, never by name similarity. They may differ from figures the company publishes.
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- Approvals & clinical trials
- Korean MFDS (data.go.kr) · US FDA openFDA — updated weekly
- Key disclosures
- KRX KIND via OpenDART exchange filings — updated daily
- Global clinical trials
- ClinicalTrials.gov (US NIH) — sponsor-matched, updated weekly
- Financials
- DART corporate disclosure filings — annual
- Publications
- PubMed (US National Library of Medicine) — affiliation-matched, updated daily
- Patents
- KIPRIS (Korea Institute of Patent Information) — applicant-matched, updated monthly
- AI reads
- Our server logs, IP-verified every 6 hours
- AI visibility
- Measured 2026-10-01
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition